CClinicalTrials.gg
Status unknownNCT03428451Updated Dec 26, 2018

Prophylaxis Versus Treatment for TURP Syndrome.

An interventional study of NaCl 3% HS and NaCl 3% HS in Transurethral Resection of Prostate Syndrome, sponsored by Ahmed Mohamed ELbadawy. Status unknown at 1 site in Egypt. Open to male participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-12-26.

Sponsored by Ahmed Mohamed ELbadawy · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Dec 2018), so the status shown — last known as Active, not recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
Male
01

Study summary

This study is designed to investigate the usage \& effects of prophylactic HS preloading, with two different concentrations, to combat the expected dilutional hyponatremia induced by irrigating fluid absorption and to prevent the occurrence of TURP syndrome with its potential complications

Read the detailed description

The study will be conducted on 60 patients ASA class I - III BPH patients, candidates for TURP surgery using monopolar electronic resectoscope. Eligible patients will be allocated into one of three study groups (n=20 in each). Group A patients will receive NaCl 3% HS at a dose of 4 ml/kg/hr; Group B patients will receive NaCl 3% HS at a dose of 2 ml/kg/hr; while Group C patients will receive NaCl 0.9% Normal Saline(NS) at a dose of 6 ml/kg/hr. All intra-venous infusions will be started 30 minutes before the subarachnoid block, and continued all through the procedure at the same specific rate for each infusion. Vital signs [mean BP, HR, CVP \& oxygen saturation (spO2)] will be recorded. Plasma electrolytes (sodium, potassium, chloride)and serum osmolality (mOsm) will be measured. Incidence of TUR syndrome, need for ICU admission, post-operative ventilation and total hospital stay will be noted.

02

Conditions studied

  • Transurethral Resection of Prostate Syndrome

Browse trials for

Keywords

  • TURP
  • hypertonic saline
  • TURP syndrome
  • hyponatraemia
03

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Inclusion criteria

  • ASA class I - III BPH patients

Exclusion criteria

Exclusion Criteria:

  • Patients having any condition contra-indicating regional anesthesia e.g impaired coagulation.
  • Electrolyte imbalance,
  • Uncontrolled hypertension,
  • Congestive heart failure or being allergic to local anesthetics.
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Group A (Hypertonic saline )

    patients will receive NaCl 3% HS at a dose of 4 ml/kg/hr.

    Drug: NaCl 3% HS

  • Active comparator
    Group B (Hypertonic saline)

    patients will receive NaCl 3% HS at a dose of 2 ml/kg/hr.

    Drug: NaCl 3% HS

  • Active comparator
    Group C (Normal saline)

    patients will receive NaCl 0.9% NS at a dose of 6 ml/kg/hr.

    Drug: NaCl 0.9% NS

Interventions

  • DrugNaCl 3% HS

    Hypertonic saline 3% is a type of crystalloid solution with osmolarity higher than that of plasma.

    Also known as: Hypertonic saline

  • DrugNaCl 3% HS

    Hypertonic saline 3% is a type of crystalloid solutions with osmolarity higher than that of plasma.

    Also known as: Hypertonic saline

  • DrugNaCl 0.9% NS

    Normal saline 0.9% is a type of crystalloid solution with osmolarity similar to that of plasma.

    Also known as: Normal saline

05

What researchers measure

Primary outcomes

  1. Serum sodium level measured in mEq/L

    Hyponatremia was defined as a serum sodium \< 130 mEq/L

    Time frame: 72 hours

Secondary outcomes

  1. Incidence of TURP syndrome

    Occurring TURP syndrome manifestations

    Time frame: 72 hours

  2. Need for ICU admission

    For cardio-pulmonary support(vasopressor,mechanical ventilation), neurological monitoring

    Time frame: 72 hours

06

Study locations

1 site
  • Faculty of Medicine
    Cairo, 11562, Egypt
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03428451
Lead sponsor
Ahmed Mohamed ELbadawy
Responsible party
Ahmed Mohamed ELbadawy (Ahmed Mohamed ELbadawy- Clinical investigator , Cairo University, Kasr El Aini Hospital) — Sponsor-investigator
First posted
Feb 9, 2018
Start date
Feb 10, 2018
Primary completion
Dec 2018 (estimated)
Completion
Dec 2018 (estimated)
Last update
Dec 26, 2018

Study contacts

Ahmed ELbadawy, MD
principal investigator · Faculty of medicine- Cairo University- Egypt

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion